# Zhiyi Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhiyi-biotech

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.zypharm.com.cn/
- Total disclosed funding: $68M
- Latest round: Series C (Apr 8, 2026)
- Investors on record: 12

## About

Founded in 2013 and based in Guangzhou, Guangzhou Zhiyi Biotechnology Co., Ltd., trading as Zhiyi Biotech, operates as a provider of a biopharmaceutical company that focuses on the research and development of next-generation probiotics and live biotherapeutics. The company has been approved more than 10 projects, including National 863 Special Project and Guangdong Provincial Major New Drug Creation Special Project. It has built a 10,000-square-meter R&D center and pilot plant, including two GMP standard pilot plants. Its SK08(Bacteroides fragilis) was approved for clinical trials in November 2019, Phase II clinical study for safety and tolerability of SK08 has enrolled in 2021. In April 2026, Zhiyi Biotech raised a series C+ funding from Jingyao Fund and Lehong Investment.

The company has established a technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. The main product, SK08, is an original biopharmaceutical and an in vivo biopharmaceutical developed using a new strain of Bacteroides Fragilis. The SK10 developed by the company can be used for treatment of chemotherapy-associated diarrhea.

The company's revenue is generated by providing R&D services in clinical stage of live biotherapeutics (LBPs) and next-generation probiotics (NGPs).

## Funding rounds

- Series C, Apr 8, 2026 — Jingyao Fund
- Series C, Mar 28, 2024, $14M — Guangdong Technology Financial Group, Airui Investment
- Series B, Jul 4, 2022, $15M — SDIC Venture Capital, Guangzhou Development District City Development Fund
- Series B, Sep 22, 2021, $15M — SinoKing Capital
- Series B, Dec 24, 2020, $17M — SDIC Venture Capital, Fineland Finance Holding, Korea Investment Partners (China), Guoxin Sichuang Investment Management
- Series A, Sep 6, 2018, $7.3M — Shenzhen Capital Real Estate Fund, Nantong Jinxin Tongda Investment Management, Guangzhou Shangdong Asset Management

## Investors

- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Nantong Jinxin Tongda Investment Management — Series A
- Guangzhou Shangdong Asset Management — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B
- Fineland Finance Holding — Series B
- Korea Investment Partners (China) (https://capitalatlas.ai/funds/korea-investment-partners-china) — Series B
- Guoxin Sichuang Investment Management (https://capitalatlas.ai/funds/guoxin-sichuang-investment-management) — Series B
- SinoKing Capital (https://capitalatlas.ai/funds/sinoking-capital) — Series B
- Guangzhou Development District City Development Fund (https://capitalatlas.ai/funds/guangzhou-development-district-city-development-fund) — Series B
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series C
- Airui Investment — Series C
- Jingyao Fund (https://capitalatlas.ai/funds/jingyao-fund) — Series C